Skip to main content

Site notifications

TBC CSL Behring Australia Pty Ltd

Product name
TBC
Accepted date
Jan-2024
Active ingredients
garadacimab
Proposed indication
Indicated for routine prevention of hereditary angioedema (HAE) attacks.
Application type
A (new medicine)
Publication date
Jan-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.

Help us improve the Therapeutic Goods Administration site